Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Future Rises After Positive Annual Outlook

Mon, 01st Jul 2019 10:49

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - WINNERS----------DS Smith, up 1.7%. The paper and packaging firm said it completed the sale of two packaging businesses in north west France and in Portugal to Memphis, Tennessee-based peer International Paper for EUR63 million. DS Smith said the sale honours the commitment made to the European Commission in relation to the clearance of its acquisition of Spanish packaging firm Europac, which completed in January. Last month, DS Smith had said financial 2019, which ended on April 30, was a "year of good delivery" overall, with "substantial" progress being made overseas and the integration of Europac was going well. Fellow packaging firms Smurfit Kappa and Mondi were up 2.6% and 1.7%, respectively. ----------FTSE 100 - LOSERS----------Fresnillo, down 2.9%. The Mexican gold miner was tracking spot gold prices lower, quoted at USD1,390.28 an ounce, down sharply from USD1,411.62 late Friday. Last week, gold had touched a six-year high of USD1,438.63. Additionally, Fresnillo on Monday said it has decided to align tax treatment for all of the company's underground mining operations, resulting in a USD8.0 million impact on profit for the six months to June-end. Shares in midcap gold miners Centamin and Hochschild Mining also were being hurt by the lower gold price, down 2.2% and 1.7%, respectively.----------International Consolidated Airlines Group, down 1.2%. Bernstein downgraded the airlines operator to Market Perform from Outperform. ----------FTSE 250 - WINNERS----------Future, up 9.0%. The digital media and publishing firm said full-year results will be ahead of expectations, underpinned by good audience growth within the Media division and the continued strong performance of recent acquisitions. The guidance was also attributed to a continuation of positive trends seen in the first half. Future's financial year ends September and will report annual results in November. "Future has a platform which enables it to monetise specialist content through a mixture of e-commerce, getting content users to click through to partnered retailers, events and online advertising. The plan is to feed newly-acquired assets into this platform. Newspaper and magazine publishers continue to battle falling sales and have struggled to get readers to pay for their relatively generic content, but consumers have shown a greater willingness to pay for specialist and niche content which they are unable to get elsewhere," said AJ Bell's Russ Mould.----------FTSE 250 - LOSERS----------John Laing Group, down 1.0%. Barclays started coverage on the infrastructure project investor at Equal Weight. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Tiziana Life Sciences, up 14%. The biotechnology company noted a study in which a drug similar to Foralumab was shown to delay the onset of type-1 diabetes. The phase two study of Teplizumab, an anti-CD3 antibody similar to Foralumab being developed by Provention Bio, was published in the New England Journal of Medicine. Type-1 diabetes is caused by the immune system's T cells attacking insulin-producing cells in the body. Anti-CD3 antibodies like Tiziana's Foralumab and Provention Bio's Teplizumab suppress the immune system to prevent this from happening. Teplizumab is derived from mice and was injected intravenously in patients whose relatives already have type 1 diabetes. Of the 76 patients evaluated, 72% were under 18. The patients were randomised to receive either a 14-day course of Teplizumab or placebo and tested at six-month intervals. At the end of the Teplizumab trial, 57% of participants treated with the drug had not developed diabetes compared to 28% on the placebo.----------OTHER MAIN MARKET AND AIM - LOSERS----------Hurricane Energy, down 17%. The oil and gas explorer said it will abandon and plug the Warwick Deep well after it did not produce at commercial rates. Hurricane had drilled the offshore North Sea well to 1,964 metres, with results indicating a 712-metre horizontal section of fractured basement reservoir. However, initial analysis suggests the well found a "poorly" connected part of the fracture network within the oil column, and the well produced at non-commercial rates. Following plugging and abandoning Warwick Deep, Hurricane will move the rig to the Lincoln Crestal wall, the second of three wells on the Greater Warwick Area.----------

More News
18 Nov 2020 15:11

UK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares

UK DIRECTOR DEALINGS SUMMARY: 888 CEO Sells GBP780,000 In Shares

Read more
11 Nov 2020 20:17

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

UK TRADING UPDATE SUMMARY: Mereo To Delist From AIM Amid Nasdaq Focus

Read more
2 Nov 2020 18:14

IN BRIEF: Tiziana To Start Brazil Clinical Trial For Covid-19 Patients

IN BRIEF: Tiziana To Start Brazil Clinical Trial For Covid-19 Patients

Read more
29 Oct 2020 16:04

Court gives Tiziana capital reduction the nod

(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Thursday that the capital reduction required for the demerger of StemPrintER Sciences, and to enable the ultimate allotment of Accustem Sciences shares to its shareholders, has been sanctioned by the court.

Read more
30 Sep 2020 12:18

UK EARNINGS SUMMARY: City Pub In Signs Of Recovery After Tough Interim

UK EARNINGS SUMMARY: City Pub In Signs Of Recovery After Tough Interim

Read more
25 Sep 2020 16:05

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
17 Sep 2020 15:51

IN BRIEF: Tiziana To Kick Off Clinical Study On Foralumab

IN BRIEF: Tiziana To Kick Off Clinical Study On Foralumab

Read more
16 Sep 2020 11:55

Tiziana Plans 2020 London IPO Of StemPrintER, SPARE Assets

Tiziana Plans 2020 London IPO Of StemPrintER, SPARE Assets

Read more
24 Aug 2020 14:33

IN BRIEF: Tiziana Life Sciences Gets US Patent On TZLS-501 In Covid-19

IN BRIEF: Tiziana Life Sciences Gets US Patent On TZLS-501 In Covid-19

Read more
24 Aug 2020 14:19

Tiziana gets US patent for 'TZLS-501' antibody

(Sharecast News) - Biotechnology company Tiziana Life Sciences announced on Monday that the United States Patent and Trademark Office (USPTO) has granted a patent for methods and use of fully human monoclonal antibody 'TZLS-501' that recognised both IL-6 receptor (IL-6R) and IL-6 receptor complex with IL-6 (IL-6R/IL-6) for prophylactic and therapeutic intervention for human diseases.

Read more
21 Aug 2020 09:34

Tiziana Life Sciences Gets US Patent For Milciclib In Cancer

Tiziana Life Sciences Gets US Patent For Milciclib In Cancer

Read more
18 Aug 2020 18:36

IN BRIEF: Tiziana Gets US Patent For Foralumab As Crohn's Treatment

IN BRIEF: Tiziana Gets US Patent For Foralumab As Crohn's Treatment

Read more
5 Aug 2020 22:03

UK TRADING UPDATE SUMMARY: Airtel And Telkom Abort Kenya Combination

UK TRADING UPDATE SUMMARY: Airtel And Telkom Abort Kenya Combination

Read more
4 Aug 2020 19:16

UK TRADING UPDATE SUMMARY: Brickability Recovering Well From Pandemic

UK TRADING UPDATE SUMMARY: Brickability Recovering Well From Pandemic

Read more
4 Aug 2020 11:07

Tiziana inks four deals for development of Covid-19 treatment

(Sharecast News) - Biotechnology company Tiziana Life Sciences has signed agreements with four contract research organisations, it announced on Tuesday, to expedite the clinical development of 'TZLS-501' - a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for the treatment of Covid-19 patients.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.